Iroxanadine

SKU: orb1700328

Description

Iroxanadine (BRX-005, CAS 13480-84-5) is a novel p38 MAPK inhibitor that induces p38 phosphorylation and causes concentration-dependent relaxation of precontracted guinea pig pulmonary arteries. This small molecule is a research tool for studying p38 signaling in inflammatory pathways and vascular physiology in vitro.

Research Area

Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 203805-20-3
• MW: 260.33
• Purity: >99.99% (May vary between batches)
• Formula: C₁₄H₂₀N₄O
• SMILES: C(C1NC(=NOC1)C=2C=CC=NC2)N3CCCCC3
• Target: p38 MAPK,HSP
• Solubility: DMSO:45 mg/mL (172.86 mM)

Bioactivity

• In Vivo:
  Iroxanadine improves the survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. The addition of Iroxanadine (0.1-1 μM) to the culture medium prior to hypoxia or at the start of reoxygenation significantly reduced the caspase-dependent apoptosis.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BRX 005, BRX 235, BRX005, BRX-005, BRX235, BRX-235, Iroxanadine, p38 MAPK, p38MAPK

Compound Identifiers

PubChem CID

6421776